Imricor Medical Systems, Inc. (ASX:IMR)

Australia flag Australia · Delayed Price · Currency is AUD
1.740
0.00 (0.00%)
Jun 5, 2026, 4:10 PM AEST
Market Cap614.88M +23.4%
Revenue (ttm)438.23K -69.5%
Net Income-37.96M
EPS-0.12
Shares Out 353.38M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume52,555
Open1.745
Previous Close1.740
Day's Range1.720 - 1.750
52-Week Range1.145 - 2.250
Beta0.43
AnalystsStrong Buy
Price Target3.15 (+81.03%)
Earnings DateAug 26, 2026

About Imricor Medical Systems

Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States, Europe, and the Middle East. The company’s products include Vision-MR Ablation Catheter 2.0, a MR-compatible cardiac ablation catheter; Vision-MR Diagnostic Catheter, a MR-compatible diagnostic catheter; NorthStar mapping system, a real-time, high-resolution soft tissue imaging of MRI to guide and visualize procedures with except... [Read more]

Sector Healthcare
Founded 2006
Country United States
Stock Exchange Australian Securities Exchange
Ticker Symbol IMR
Full Company Profile

Financial Performance

In 2025, Imricor Medical Systems's revenue was $292,309, a decrease of -69.53% compared to the previous year's $959,424. Losses were -$25.32 million, -14.73% less than in 2024.

Financial numbers in USD Financial Statements

Analyst Summary

According to 4 analysts, the average rating for IMR stock is "Strong Buy." The 12-month stock price target is $3.15, which is an increase of 81.03% from the latest price.

Price Target
$3.15
(81.03% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Imricor Medical Systems Transcript: AGM 2026

The meeting reviewed significant clinical and regulatory milestones, highlighted a strengthened financial position, and approved key board elections, incentive plans, and auditor ratification. No questions were raised, and voting results will be released to the ASX.

4 weeks ago - Transcripts

Imricor Medical Systems Slides: FY 2026

Imricor Medical Systems has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 7, 2026.

4 weeks ago - Filings

Imricor Medical Systems Slides: Investor presentation

Imricor Medical Systems has posted slides in relation to its latest quarterly earnings report, which was published on May 3, 2026.

4 weeks ago - Filings

Imricor Medical Systems Earnings release: Q1 2026

Imricor Medical Systems released its Q1 2026 earnings on April 27, 2026, summarizing the period's financial results.

5 weeks ago - Filings

Imricor Medical Systems Earnings Call Transcript: H2 2025

Major regulatory and clinical milestones achieved, including first-in-human MRI-guided VT ablation and FDA clearance for NorthStar. Revenue declined due to trial-related non-revenue procedures, but commercial readiness and pipeline growth position the company for significant expansion as approvals progress.

3 months ago - Transcripts

Imricor Medical Systems Annual report: H2 2025

Imricor Medical Systems has published its H2 2025 annual report on February 24, 2026.

3 months ago - Filings

Imricor Medical Systems Slides: H2 2025

Imricor Medical Systems has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 24, 2026.

3 months ago - Filings

Imricor Medical Systems Earnings release: H2 2025

Imricor Medical Systems released its H2 2025 earnings on February 24, 2026, summarizing the period's financial results.

3 months ago - Filings

Imricor Medical Systems Earnings release: Q4 2025

Imricor Medical Systems released its Q4 2025 earnings on January 27, 2026, summarizing the period's financial results.

4 months ago - Filings

Imricor Medical Systems Earnings release: Q3 2025

Imricor Medical Systems released its Q3 2025 earnings on October 21, 2025, summarizing the period's financial results.

8 months ago - Filings

Imricor Medical Systems Earnings Call Transcript: H1 2025

Revenue declined 52% year-over-year due to lower equipment sales, while net loss rose to $13.1 million, driven by fair value changes and increased investment in sales and R&D. Regulatory progress continues, with Northstar FDA approval and U.S. launch expected by year-end, and a strong cash position supports ongoing expansion.

10 months ago - Transcripts

Imricor Medical Systems Quarterly report: H1 2025

Imricor Medical Systems has published its H1 2025 quarterly earnings report on August 25, 2025.

10 months ago - Filings

Imricor Medical Systems Slides: H1 2025

Imricor Medical Systems has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 25, 2025.

10 months ago - Filings

Imricor Medical Systems Earnings release: H1 2025

Imricor Medical Systems released its H1 2025 earnings on August 25, 2025, summarizing the period's financial results.

10 months ago - Filings

Imricor Medical Systems Earnings release: Q2 2025

Imricor Medical Systems released its Q2 2025 earnings on July 27, 2025, summarizing the period's financial results.

11 months ago - Filings